Mark Peterson

Serina Therapeutics has answered the FDA's challenge. A 30-day clock now ticks on its novel Parkinson's therapy and its disruptive drug delivery platform.

Darling Ingredients' new venture with Tessenderlo isn't just a merger; it's a strategic move to dominate the booming collagen and nutrition market.

A $3 billion drop in assets at AllianceBernstein, driven by client withdrawals in a flat market, signals a deeper challenge for active asset managers.

Beyond the headlines of a $592M debt reduction, McGraw Hill is executing a dual strategy: fortifying its finances to fund a digital and AI-driven future.

With a 2026 launch looming, Nuvalent adds a proven oncology dealmaker to its board, signaling a strategic pivot from R&D to market assault.

SBM Offshore’s €141M share buyback is more than routine. It’s a strategic move to boost EPS, signal confidence, and fund its energy transition goals.

A struggling interactive entertainment firm bets its future on gold, targeting Malaysia's booming market. A look at the high-stakes pivot shaking up BHAT.

With a new patent, this biotech targets the massive orthopedics market. But can its novel fibroblast therapy overcome steep financial and clinical hurdles?

NiCE's local data center launch in South Africa is more than a new product; it's a strategic play on compliance and advanced AI to capture the continent.

Early Phase 1 data for VTP-1000 shows promise, but can this novel immunotherapy challenge a crowded market and change life for 80 million patients?

A CFO's $30k stock purchase is more than a headline. It's part of a pattern of insider confidence at JFB, signaling a bullish outlook.

New data shows Kazia's paxalisib dismantles metastatic drivers and reignites immunity, signaling a strategic disruption in advanced breast cancer treatment.

A new partnership between Telix and Varian aims to fuse precision diagnostics with adaptive radiotherapy, a strategic move set to disrupt the cancer care market.

Capital Power unveils a $3B deal with Apollo to buy U.S. gas plants while securing a major deal to power Alberta's AI boom, a bold dual strategy.

Husqvarna unveils a massive cost-cutting plan alongside ambitious growth and green targets. Can this strategic pivot secure its future market leadership?

Beyond a simple FDA approval, Amneal's entry into the epinephrine vial market is a calculated move to fix a broken supply chain and drive growth.

A routine dividend from Imperial Petroleum reveals a powerful strategy: a debt-free balance sheet and cash-funded growth in a volatile shipping market.

Klaviyo appoints a veteran scaler as co-CEO in a bold move to let its founder focus solely on AI. Is this the new leadership model for tech dominance?

A new partnership aims to turn dusty tape libraries into revenue streams using AI, marking a major strategic shift for a legacy hardware maker.

Celldex is launching a pivotal Phase 3 trial for a drug that could be the first advanced therapy for two debilitating and untreated chronic hive conditions.